Petrelintide: The Standalone Amylin Analog Trial Explained
TRIAL-000023
Direct Answer
Petrelintide is a real, investigational amylin receptor agonist from Roche and Zealand Pharma. Unlike most drugs on this site, it doesn't act on the GLP-1 receptor at all, it targets the amylin pathway specifically, on its own rather than combined with GLP-1. It is not FDA-approved.
Real, Reported Phase 2 Results
In the ZUPREME-1 trial, petrelintide produced 10.7% weight loss at 42 weeks, real, meaningful results for a standalone amylin therapy, though generally more modest than combination GLP-1/amylin approaches like CagriSema or amycretin.
Why This Matters for the Broader Field
Petrelintide's results help researchers understand how much of the weight-loss effect in combination drugs comes from the amylin component specifically versus the GLP-1 component, real, useful comparative data for the field.
Current, Real Status
Phase 3 trials were announced in April 2026 based on these Phase 2 results. Petrelintide remains investigational.
References
- ZUPREME-1 Phase 2 trial results (March 2026)
- Real-time pipeline tracker: GLP-1 + Amylin Combinations 2026
Petrelintide vs. Combination Amylin Therapies
| Drug | Approach | Real Weight Loss (Phase 2) |
|---|---|---|
| Petrelintide | Amylin only, no GLP-1 | ~10.7% (42 wks) |
| Amycretin | GLP-1 + amylin, single molecule | ~14.5-15.2% |
| CagriSema | GLP-1 + amylin, co-formulated | ~20.4-22.7% |
Petrelintide's more modest results as a standalone therapy help researchers understand how much of the effect in combination drugs comes from the amylin component specifically. See DietApp's amycretin trial page and CagriSema REDEFINE trials page for the combination approaches.
Frequently Asked Questions
Does petrelintide affect blood sugar like GLP-1 drugs do? Amylin's primary role is slowing gastric emptying and promoting satiety, distinct from GLP-1's direct insulin-stimulating effect.
Why is a standalone amylin drug useful if combinations work better? It may suit patients who don't tolerate GLP-1 medications well, or those wanting a different mechanism entirely.
When is Phase 3 expected to conclude? Not established; Phase 3 was announced in April 2026, with results still pending.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.
petrelintide-the-standalone-amylin-analog-trial-explained